The present study was undertaken to examine the effect of Homocysteine (Hcy) and nitric oxide (NO) levels on specific Computed Axial Tomography (CAT) measurements, as global brain atrophy and brain vascular lesion in Alzheimer Disease (AD) and in Vascular Dementia (VD) patients. We have analysed serum Hcy and NO levels in AD patients and compared the findings with those in VD patients and control subjects. Moreover we have studied the correlation of Hcy and NO levels with cognitive impairment and brain atrophy determined by Computed Axial Tomography. Hcy serum levels significantly increased in all demented patients compared to control group, independently from the dementia type. On the contrary, no differences were observed in NO serum levels between groups. Moreover, we found significant correlation between Hcy and brain atrophy in both demented groups; whereas NO levels correlated only in AD, but not in VD patients. The pathogenic effect of Hcy either in AD and VD patients appears to confirm a definitive vascular component in AD. As regards NO, our results highlight the role of NO as a beneficial molecule in AD and support the use of NO mimetics as an antineurodegenerative therapy for AD patients.
Introduction
Alzheimer disease (AD) has long been considered to be a primarily degenerative brain disease, but today it is known that vascular lesions are rather common in AD subjects [1] . In fact, it is now recognized that vascular risk factors significantly increase the risk of developing AD. In particular, there is growing evidence that elevated blood concentration of Homocysteine (Hcy) is a strong risk factor for AD [2] . Moreover, increased circulating Hcy has been associated with cerebrovascular disease and may lead to cognitive impairment [3] . In non-demented elderly populations, plasma Hcy is inversely associated with poor performance at test of global cognitive function [4, 5] and specific cognitive skills [6] . Moreover, Hcy was associated with atrophy of the medial temporal lobe and patients with higher Hcy levels had a more rapid rate of atrophy over time [7] . Case-control [8, 9] or cross-sectional studies [10, 11] have reported a strong association between AD and elevated Hcy concentrations, while other studies reported no association [12, 13] . Hence, there is not consistent evidence of a prospective association between Hcy and AD and it is not clear whether elevated plasma Hcy may be a primary causative factor or simply a marker of coexisting vascular disease in AD patients [9] . Recent studies reported that Hcy, through the increased formation of asymmetric dimethylarginine, an endogenous competitive inhibitor of nitric oxide (NO) synthase, may contribute to the pathology of AD by inhibiting endothelial NO production.
NO is a versatile, diffusible messenger implicated in various physiological functions, ranging from dilation of blood vessels and muscle relaxation to immune responses and potentiation of synaptic transmission. It has been reported that impaired NO homeostasis may promote endothelial cell damage and may expose end-organs to vasculopathy [14] . De la Torre et al. [15] proposed that when basal NO levels drop, endothelial cells become compromised as a result and nutrient delivery to brain cells falls below a suboptimal concentration. This event could trigger a dysfunctional metabolic cascade which in time will disrupt the major source of energy fuel in the brain. Consequently, NO seems to play a critical role in signal transduction cascades that, if compromised, may contribute to the symptoms of cognitive impairment and dementia that characterize AD. In fact, Tarkowski et al. [16] demonstrated an inverse correlation between the concentrations of NO in the cerebrospinal fluid of AD patients and the degree of cognitive impairment.
Starting from these considerations and in the frame of our current studies on AD and neurodegenerative dementia [13] , the present study was undertaken to examine the effect of Hcy and NO levels on specific Computed Axial Tomography (CAT) measurements, as global brain atrophy and brain vascular lesion in AD patients. Moreover, in order to understand if the possible effect is a primary causative factor or simply a marker of coexisting vascular disease in AD patients, we carried out the study also on Vascular Dementia (VD) patients.
Materials and Methods

Study population
Subjects were obtained from the Regional Hospital of Treviso/Alzheimer Evaluation Unit. For this study, 85 subjects were recruited and divided into three groups: (i) 59 AD patients (73-88 years), (ii) 8 VD patients (76-88 years) and (iii) 18 control healthy subjects (62-82 years). All the patients underwent a complete diagnostic work-up according to current standards, which include general and neurological examinations, a standard neuropsychological assessment, and routine blood and urine screening investigations to rule out secondary dementias. The presence of previous or present major psychiatric disorders, serious neurological diseases, severe and uncontrolled arterial hypertension, diabetes mellitus, renal, hepatic or respiratory failure, anaemia or malignancies were exclusion criteria. Diagnosis of AD was determined using criteria set by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA), while VD patients fulfilled diagnostic criteria of the National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) [17] . All subjects had undergone a Mini Mental State Examination (MMSE) and a Clinical Dementia Rating Scale (CDRS) [18] .
Blood Sampling and Biochemical Measurements
All blood samples were drawn from each participant after a fasting period of 10-12 h in Vacutainer tubes without anticoagulant. Tubes were centrifuged at 1500 rpm for 30 min and samples were stored at -80
• C. Total serum homocysteine (Hcy) and serum nitric oxide (NO) concentration were determined as already reported [13] . Briefly, Hcy concentration was measured by HPLC, after the reduction of disulphide bonds with dithiothreitol and deproteinization with sulphosalicyclic acid using "Bio-Rad HPLC Hcy Assay" (Herculaes, CA, USA). NO concentration was determined after the reduction of nitrate to nitrite by a colorimetric assay kit (Nitrate/Nitrite colorimetric Assay Kit Inalco, Mi, Italy) based on Griess reaction.
Structural Neuroimaging Evaluation
Cerebral vascular lesions, cortical and subcortical atrophy were determined by CAT as already reported [13] . Section orientation was parallel to the plane of the temporal lobe: that is 20
• caudal to the orbitomeatal line. 2-mm thick sections were taken along the breadth of the temporal lobe from the floor of the middle cranial fossa to the inferior aspect of the orbit [19] . Cerebral vascular lesions were determined with reference to the cerebral vascularity hierarchical scale. Three types of lesions were visually rated from CAT films: (i) degree of diffuse hypodensity of the white matter (leukoarairosis), (ii) focal areas of hypodensity with indistinct boundaries (patchy and fuzzy hypodensities) and (iii) well-defined areas of marked and homogeneous hypodensity with a well-defined and regular contour (lacunes). The rating scale range from 0 (absence of vascular anomalies) to 6 (serious vascular anomalies). Cerebral vascular lesions are considered absent or minor, and so compatible with the presence of a cerebral degenerative disease, when vascular score is 0 or 1. In other cases, when vascular score is 2 or higher, a cerebral vascularity cause for the cognitive impairment is present. In fact, this rating scale is considered to be a sensitive instrument to capture the pathogenetic link between the regions, gravity of vascular lesions and the cognitive impairment level [20] . Cortical atrophy was quantified separately in 4 regions defined as follows: frontal, temporal, parietal and occipital. Subcortical atrophy was quantified separately in 4 regions: insula, basal nuclei, lateral ventricles and tegmentum. Both atrophy measurements were determined using a conventional numeric scale ranging from 0 (no lesion) to 1, 2, 3 (minor, moderate, severe lesions).
Statistical analysis
Statistical analysis was performed using the SPSS statistical software package. Biochemical measurements and cerebral atrophy scores were compared by non-parametric tests: Kruskal-Wallis test followed by Mann-Whitney U-test for 2 independent samples. Spearman's rank order correlation method was used to calculate the correlation and the level of significance between biochemical measurements and structural neuroimaging scores.
Results
The three groups analysed were not different regarding age. Both AD and VD showed a moderate cognitive decline, as revealed by MMSE and CDRS scores (Table 1) . Results are expressed in mean ± SD. Statistical analysis: Kruskal-Wallis test followed by Mann-Whitney U-test for 2 independent samples *p<0.05 against control. Table 1 Descriptive characteristics of the analysed groups. Table 2 shows the biochemical measurements obtained in the groups: Hcy serum levels were significantly (p<0.05) higher in AD patients compared to those determined in the control group. Moreover, AD patients had Hcy serum levels significantly (p<0.05) lower respect to VD patients. VD patients had Hcy serum levels significantly (p<0.001) higher respect to control subjects. On the contrary, no differences were observed in NO serum levels either in AD and in VD patients respect to control. 
Table 3
Structural Neuroimaging Evaluation scores of the analysed groups.
In Table 4 is reported the correlation analysis made in order to investigate the possible associations between Hcy and NO levels with structural neuroimaging score in AD and VD patients. The correlation of Hcy levels with structural neuroimaging scores resulted to be positive either in AD and VD patients, even if resulted to be significant only for vascular and subcortical atrophy scores. In particular, the correlation with vascular score resulted to be significant at the level 0.05 and was low for AD (r=0.36) and high for VD (r=0.608) patients. Regarding subcortical atrophy score, the correlation resulted to be significant at the 0.001 level for AD patients and at the level 0.05 for VD patients, moreover it was low for AD (r=0.332) and high for VD (r=0.730).
Considering NO correlation analysis, it resulted to be significant at the 0.05 level only for AD patients even if the correlation was weak. In fact, there was a low positive correlation with MMSE score (r=0.320), and a low negative correlation with CDRS (r=-0.336), with cortical (r=-0.330) and subcortical (r=-0.330) atrophy scores. No significant correlation was observed for vascularity evaluation. Table 4 Correlation analysis among Hcy and NO serum concentrations and examined variables.
Discussion
Hcy levels have been related to cerebral macro-and microangiopathy, endothelial dysfunction, impaired NO activity, and increased oxidative stress [21, 22] . Our results agree with recent studies in which plasma Hcy levels in AD and VD groups were increased compared with controls, confirming the involvement of elevated Hcy with dementia [8, 23] . Moreover, Nilsson et al. [24] observed an elevated Hcy concentration in early onset AD subjects compared with control group, indicating that elevated plasma Hcy level might be a reflection of concomitant vascular disease in AD patients. Recently, it has been demonstrated that in cell cultures, Hcy can directly cause brain damage through several mechanisms [25, 26] . These negative effects of Hcy could be assumed as a partial explanation of the correlation found in this study. In fact, we report in demented patients (either AD or VD) a significant and positive correlation between Hcy and structural neuroimaging evaluations, such as vascular score and subcortical atrophy score. An association between elevated Hcy levels and brain atrophy has been already reported in healthy, elderly non-demented subjects [27] . Moreover, Sachdev et al. [28] reported a significant correlation between Hcy levels and subcortical -but not cortical -atrophy. In our data, Hcy correlates with the same structural neuroimaging evaluations in AD and VD patients, confirming the role of Hcy as a vascular risk factor in AD patients. Moreover Hcy resulted to be involved in pathological mechanisms leading to cerebral vascular lesions and subcortical atrophy, independent to dementia type. Several studies have demonstrated the role of NO as a protective molecule in central nervous system such as a role in neurotransmission [29] , increased synaptic efficacy of neurons in the hippocampus [30] , and regulation of cerebral blood flow [31] . In our study, NO levels were similar in demented patients as compared to healthy controls, confirming Tarkowski et al. [16] results that suggest that NO production in AD is primarily not due to an inflammatory response, but to the basal nitrate production. The inverse correlation between NO levels and brain atrophy in AD patients may suggest a neuroprotective effect of NO in AD, probably correlated with NO vasodilating activity. Therefore, higher NO levels could be involved in amelioration of cerebral circulation and could lead to slowing down of the brain atrophy phenomenon. This data support recent data that demonstrated an inverse correlation between intratecal NO levels and the degree of intellectual impairment in AD patients [16] .
The different result in the NO correlation analysis between AD and VD patients could be explained by the different target of the two dementia types. In fact, while AD is characterized mainly by loss of neurons, decrease of the arborisation of the dendrites, presence of neurofibrillary tangles and senile plaques, VD is a disease affecting the myelin and, as a consequence, characterized by increased levels of myelin but not axonal degradation products [32] . Moreover, Hyman et al. [33] showed that NOS-containing neurons are selectively spared in AD subjects, even in a severely affected regions of the brain (as the hippocampus), probably due to concomitantly increased expression of superoxide dismutase and thereby increased resistance against superoxide toxicity. Thus, the intrathecal production of NO and NO released by degenerating neurons may exert neuroprotective roles in AD protecting neurons from superoxide-triggered toxicity, preventing or counteracting cell damage, effects that lack in VD patients.
In summary, the pathogenic effect of Hcy either in AD and VD patients appears to confirm a definitive vascular component in AD. As regards NO, our results highlight the role of NO as a beneficial molecule in AD. Our results suggest possible therapeutic strategies for AD based on the increase of NO level in cerebral vessels. Recently, it has been proposed that the use of a NO mimetic, a novel nitrate ester, GT1061, is able to cross the blood brain barrier and achieve brain concentrations that are higher than those found in plasma. Evidence suggests that NO mimetics may operate via multiple biochemical signalling pathways, providing a combined neuroprotective and cognitionenabling approach to antineurodegenerative therapy [34] .
Some caveats should be emphasized: (i) relative small group of patients, and (ii) non comparative group size. For these reasons we applied a non parametric statistical analysis and some note of caution must be used in the extrapolation of our results to wider populations. Moreover, even if we knew that nitrate levels are dependent on diet, we have analyzed the nitrate levels because it has been demonstrated that the measurement of NO − 3 accurately reflects NO activity in vivo [35] .
